MedWatch

Analyst: Genmab share price may double

In an analysis, Jyske Bank estimates that Genmab's stock price does not reflect the potential of the company's pipeline, although it highlights one large risk within this share.

Photo: Lars Møller / Genmab / PR

Genmab has struggled so far in 2021, but certain signs indicate the share may be regaining its momentum, according to an analysis from the Danish bank Jyske Bank.

Strong sales figures, fast-track acceptance of the drug tisotumab and the prospects of many new developments in the second half-year may generate tailwind for the company.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs